foxo4-dri peptide human trial alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice FOXO4-DRI improves spermatogenesis in aged
FOXO4 DRI improves spermatogenesis in aged mice through reducing senescence associated secretory phenotype secretion from Leydig cells ScienceDirect FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv FOXO4 DRI 10mg
Pay in 4 interest-free payments of $7.37 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4



